# Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells

> **NCT06420076** · PHASE1,PHASE2 · RECRUITING · sponsor: **Essen Biotech** · enrollment: 60 (estimated)

## Conditions studied

- T Cell Lymphoma
- T Cell Leukemia
- T-cell Acute Lymphoblastic Leukemia
- T-Cell Lymphoma of CNS
- T Cell Prolymphocytic Leukemia
- T Cell Childhood ALL

## Interventions

- **BIOLOGICAL:** CD5/CD7 CAR-T

## Key facts

- **NCT ID:** NCT06420076
- **Lead sponsor:** Essen Biotech
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-10
- **Primary completion:** 2025-12-10
- **Final completion:** 2026-12-28
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2024-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06420076

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06420076, "Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06420076. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*